UBS AM’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JHC
UBS AM's RLMD Position: Q3 2026 in Review
UBS AM opened a new position in Relmada Therapeutics (RLMD) in Q3 2026: 209 shares worth $788. The stake represents ﹤0.01% of the portfolio and ranks #4148 among its holdings. This is a return to the name: UBS AM previously reported a position in RLMD as recently as Q3 2022.
UBS AM first reported a position in RLMD in Q2 2020 and has held it in 9 quarters since. The position peaked at $839K in Q3 2022. 105 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.
- UBS AM held 209 shares of Relmada Therapeutics worth $788 as of Q3 2026.
- Relmada Therapeutics was a new UBS AM position in Q3 2026.
- Relmada Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4148 holding.
- UBS AM first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 9 quarters since.
- UBS AM's Relmada Therapeutics position peaked at $839K in Q3 2022.
- 105 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.